Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York.
Center for Health Sciences Research, Rutgers Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey.
JAMA Netw Open. 2022 Mar 1;5(3):e223821. doi: 10.1001/jamanetworkopen.2022.3821.
Medication for opioid use disorder (MOUD) is the criterion standard treatment for opioid use disorder (OUD), but nationally representative studies of MOUD use in the US are lacking.
To estimate MOUD use rates and identify associations between MOUD and individual characteristics among people who may have needed treatment for OUD.
DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional, nationally representative study using the 2019 National Survey on Drug Use and Health in the US. Participants included community-based, noninstitutionalized adolescent and adult respondents identified as individuals who may benefit from MOUD, defined as (1) meeting criteria for a past-year OUD, (2) reporting past-year MOUD use, or (3) receiving past-year specialty treatment for opioid use in the last or current treatment episode.
The main outcomes were treatment with MOUD compared with non-MOUD services and no treatment. Associations with sociodemographic characteristics (eg, age, race and ethnicity, sex, income, and urbanicity); substance use disorders; and past-year health care or criminal legal system contacts were analyzed. Multinomial logistic regression was used to compare characteristics of people receiving MOUD with those receiving non-MOUD services or no treatment. Models accounted for predisposing, enabling, and need characteristics.
In the weighted sample of 2 206 169 people who may have needed OUD treatment (55.5% male; 8.0% Hispanic; 9.9% non-Hispanic Black; 74.6% non-Hispanic White; and 7.5% categorized as non-Hispanic other, with other including 2.7% Asian, 0.9% Native American or Alaska Native, 0.2% Native Hawaiian or Pacific Islander, and 3.8% multiracial), 55.1% were aged 35 years or older, 53.7% were publicly insured, 52.2% lived in a large metropolitan area, 56.8% had past-year prescription OUD, and 80.0% had 1 or more co-occurring substance use disorders (percentages are weighted). Only 27.8% of people needing OUD treatment received MOUD in the past year. Notably, no adolescents (aged 12-17 years) and only 13.2% of adults 50 years and older reported past-year MOUD use. Among adults, the likelihood of past-year MOUD receipt vs no treatment was lower for people aged 50 years and older vs 18 to 25 years (adjusted relative risk ratio [aRRR], 0.14; 95% CI, 0.05-0.41) or with middle or higher income (eg, $50 000-$74 999 vs $0-$19 999; aRRR, 0.18; 95% CI, 0.07-0.44). Compared with receiving non-MOUD services, receipt of MOUD was more likely among adults with at least some college (vs high school or less; aRRR, 2.94; 95% CI, 1.33-6.51) and less likely in small metropolitan areas (vs large metropolitan areas, aRRR, 0.41; 95% CI, 0.19-0.93). While contacts with the health care system (85.0%) and criminal legal system (60.5%) were common, most people encountering these systems did not report receiving MOUD (29.5% and 39.1%, respectively).
In this cross-sectional study, MOUD uptake was low among people who could have benefited from treatment, especially adolescents and older adults. The high prevalence of health care and criminal legal system contacts suggests that there are critical gaps in care delivery or linkage and that cross-system integrated interventions are warranted.
阿片类药物使用障碍(MOUD)的药物治疗是阿片类药物使用障碍(OUD)的标准治疗方法,但美国缺乏全国性的 MOUD 使用代表性研究。
评估 MOUD 的使用率,并确定 MOUD 与可能需要 OUD 治疗的人群的个体特征之间的关联。
设计、地点和参与者:这是一项使用美国 2019 年全国药物使用和健康调查的具有全国代表性的横断面研究。参与者包括社区为基础的、非机构化的青少年和成年受访者,他们被认为可能需要 MOUD 治疗,定义为(1)符合过去一年 OUD 标准,(2)报告过去一年 MOUD 使用,或(3)在过去或当前治疗期间接受过去一年专门用于治疗阿片类药物使用的治疗。
主要结果是与非 MOUD 服务和无治疗相比,接受 MOUD 治疗。分析了与社会人口特征(如年龄、种族和民族、性别、收入和城市性);物质使用障碍;以及过去一年的医疗保健或刑事法律系统接触。使用多项逻辑回归比较接受 MOUD 治疗的人与接受非 MOUD 服务或无治疗的人的特征。模型考虑了倾向、使能和需求特征。
在可能需要 OUD 治疗的 2206169 名有代表性的人群中(55.5%为男性;8.0%为西班牙裔;9.9%为非西班牙裔黑人;74.6%为非西班牙裔白人;7.5%被归类为非西班牙裔其他,其他包括 2.7%的亚洲人、0.9%的美洲原住民或阿拉斯加原住民、0.2%的夏威夷原住民或太平洋岛民,以及 3.8%的多种族),55.1%的人年龄在 35 岁或以上,53.7%的人有公共保险,52.2%的人居住在大城市地区,56.8%的人过去一年有处方 OUD,80.0%的人有 1 个或多个共病物质使用障碍(百分比是加权的)。只有 27.8%的需要 OUD 治疗的人在过去一年接受了 MOUD。值得注意的是,没有青少年(12-17 岁),只有 13.2%的 50 岁及以上的成年人报告过去一年使用 MOUD。在成年人中,与没有治疗相比,过去一年接受 MOUD 的可能性较低,年龄在 50 岁及以上的成年人与 18 至 25 岁的成年人(调整后的相对风险比[ARR],0.14;95%置信区间,0.05-0.41)或收入中等或更高的成年人(例如,50000-74999 美元与 0-19999 美元;ARR,0.18;95%置信区间,0.07-0.44)。与接受非 MOUD 服务相比,接受 MOUD 的可能性在至少接受过一些大学教育的成年人中更高(与高中或以下学历相比;ARR,2.94;95%置信区间,1.33-6.51),而在小都市地区则较低(与大都市地区相比,ARR,0.41;95%置信区间,0.19-0.93)。尽管与医疗保健系统(85.0%)和刑事法律系统(60.5%)的接触很常见,但大多数遇到这些系统的人并没有报告接受 MOUD(分别为 29.5%和 39.1%)。
在这项横断面研究中,在可能需要治疗的人群中,MOUD 的使用率较低,尤其是青少年和老年人。医疗保健和刑事法律系统接触的高患病率表明,在提供护理或衔接方面存在重大差距,需要跨系统的综合干预措施。